KR101723357B1 - Genetic polymorphic markers for determining type of sensitive skin and use thereof - Google Patents

Abstract

The present invention relates to a skin type sensitive marker diagnostic marker comprising one or more single base polymorphic markers selected from single base polymorphism (SNP) markers, a composition comprising an agent capable of detecting said marker, a kit comprising said composition Or a microarray and a method of providing information on the sensitivity of the skin type using the marker. The single nucleotide polymorphic markers of the present invention provide accurate information on the individual's skin type and thus can develop personalized cosmetics and develop customized active ingredients.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention [0001] The present invention relates to a sensitive skin type genetic polymorphism marker,

The present invention relates to a skin type of sensitivity marker for diagnosis comprising at least one single base polymorphism marker selected from single base polymorphism (SNP) markers capable of judging whether or not sensitive skin is present, and an agent capable of detecting the marker A kit, or a microarray containing the composition, and a method for providing information on the sensitivity of the skin type using the marker.

Human skin has different skin condition for each individual. In particular, even skin types of the same age and the same skin type can vary greatly depending on the internal and external environment of each individual. As the scientific civilization develops, there are more and more cases in which the skin is severely affected by exposure to various polluted environments, exposure to ultraviolet rays due to destruction of the ozone layer, various stresses, and the like, resulting in deterioration of skin function and even skin troubles . Accordingly, there is a growing demand for functional cosmetics that can improve or maintain the condition of the skin.

However, at present, it is difficult to obtain complete trust in the skin condition information because the judgment of the skin condition for each user is mainly about the skin condition of the user through simple skin test and simple skin test. In addition, functional cosmetics currently on the market are not aimed at individuals, but are universal. Therefore, there are many limitations in finding suitable cosmetics for users. Therefore, there is almost no system to provide customized cosmetics by precisely diagnosing skin condition by approaching scientific basis.

With the increasing demand for customized cosmetics according to skin characteristics, it is required to establish a systematic standard of skin classification and to characterize product prescription accordingly. However, the current water balance classification standard used for skin classification is not able to accurately classify the skin. In addition, in a method of providing customized cosmetics by measuring the skin condition of the prior art, in order to check the current skin condition of the user, the condition of the skin wrinkles is grasped by an image analyzer system using mainly a replica plate in case of wrinkles, In the case of skin whitening, a change in erythema or skin color is measured using a mexameter and a colorimeter. In the case of skin moisturizing, a moisturizing amount is measured mainly using a corneometer have. These measurement methods simply represent the physical state of the skin surface by numerical values and may vary depending on the program to be measured. Therefore, there is a fear that errors may occur in evaluating the degree of improvement of the subject. In addition, in the case of the visual evaluation of the tester and the evaluation of the questionnaire by the tester, the subjective aspect greatly plays a role, which makes it difficult to objectively and precisely evaluate the skin condition of the subject.

Under these circumstances, the present inventors constructed a scientific skin classification standard by grasping the genetic characteristics that determine the skin characteristics of an individual, developed a personalized custom active ingredient on the basis thereof, developed customized cosmetics according to skin characteristics through various product segmentation (SNP) markers having a significant correlation with skin sensitivity were selected to confirm whether the skin type is sensitive or not, thereby completing the present invention.

It is an object of the present invention to provide a marker for the sensitivity diagnosis of skin type comprising at least one single base polymorphism marker selected from single base polymorphism (SNP) markers capable of judging whether sensitive skin is present.

Another object of the present invention is to provide a composition for diagnosing sensitivity of skin type comprising a probe capable of detecting a marker for detecting sensitivity of the skin type or an agent capable of amplifying.

It is another object of the present invention to provide a skin type sensitive diagnostic kit or microarray comprising the composition for diagnosing sensitivity of the skin type.

Yet another object of the present invention is to provide a method for providing information on the sensitivity of a skin type, which comprises identifying a polymorphic site of the single nucleotide polymorphism marker.

In one aspect of the present invention, the present invention provides a skin type diagnostic marker for susceptibility, comprising at least one single nucleotide polymorphism marker selected from single nucleotide polymorphism (SNP) markers capable of judging a sensitive skin condition to provide.

In the present invention, the term "polymorphism" refers to a case where two or more alleles exist in one locus. Of the polymorphic sites, only a single base differs from a polymorphism region to a single base polymorphism (single nucleotide polymorphism, SNP). Preferred polymorphic markers have two or more alleles exhibiting an incidence of 1% or more, more preferably 10% or 20% or more, in the selected population.

The term "allele " in the present invention refers to various types of genes that exist on the same locus of a homologous chromosome. Alleles are also used to represent polymorphisms, for example, SNPs have two kinds of bialles.

In the present invention, the term "rs_id " means rs-ID, which is an independent marker assigned to all SNPs initially registered by the NCBI that has started accumulating SNP information since 1998. [ The rs_id shown in the above table means the SNP marker which is the polymorphism marker of the present invention.

The term "skin type " in the present invention means a skin type of an individual to be measured or diagnosed. The type of skin that can be measured by the SNP of the present invention is not limited but may be sensitive. According to one embodiment of the present invention, the inventors classified the subject's skin type as sensitive skin or less sensitive skin, skin with metal allergy sensitive to metal in sensitive skin, or skin without metal allergy which is not sensitive to metal. Since the single nucleotide polymorphic marker of the present invention enables accurate skin type measurement, information on the changed skin type of skin contacted with the active ingredient can also be provided.

Preferably, the single nucleotide polymorphism marker may be at least one single nucleotide polymorphism marker selected from the single nucleotide polymorphism markers set forth in Tables 3 to 5. The single nucleotide polymorphic markers shown in Tables 3 to 5 indicate whether the skin type is sensitive, and in particular, the single nucleotide polymorphism markers shown in Table 5 indicate that the skin type, which can be a measure of sensitive skin, Or not.

Whether the single nucleotide polymorphism marker of the present invention was diagnosed with the skin type was determined by measuring the frequency of each marker. Such significance is not limited to p-values such as less than 0.05, less than 0.01, less than 0.001, less than 0.0001, less than 0.00001, less than 0.000001, less than 0.0000001, less than 0.00000001, or less than 0.000000001 p-value. Preferably, the p-value may be less than 0.01, more preferably the p-value may be less than 0.001.

The polymorphic markers of the present invention are the markers shown in Tables 3 to 5, wherein when the polymorphic site of the polymorphic site of the individual polymorphic marker is a minor allele, a non-sensitive skin (control ) And the frequency of frequency of susceptible skin test cases are judged to be the skin of the group having a high frequency, and when the polymorphic site is a major allele, the non-sensitive skin shown in Tables 3 to 5 The frequency of the test group, which is the control group and the sensitive skin, is the marker which can be judged as the skin of the low frequency group. For example, when the 153923073th base of the chromosome 6 of the individual is T, the frequency of the test group is higher than that of the test group. Therefore, the skin of the individual having the minority allele T can be judged as a sensitive skin It is. If the 153923073 base of the chromosome 6 of the individual is C, which is the majority allele, the frequency of the control group is lower in Table 3, which can be judged as a non-sensitive skin as a control group.

In Table 5, which shows metal allergy-related markers indicating susceptibility to metals in sensitive skin, the minor allele of the polymorphic site is a minor allele. The control group and metal-sensitive skin allergic skin test group were judged to have a high frequency of water frequency. When the polymorphic base group was a major allele, the control group, which is skin without metal allergy shown in Table 5, And metal allergic skin. The frequency of the frequency is low, and it can be judged as the skin of the low frequency group. For example, when the 67052074th base of the chromosome 10 of an individual is G, the frequency of the test group is higher than that of the test group. Therefore, the skin of the individual having the minority allele G is judged to be a metal allergy skin You can. If the 67052074 base of the chromosome 10 of the individual is A, which is the majority allele, the frequency of the control group is lower in Table 5, which can be judged as a skin without metal allergy, which is a control group.

More preferably, Table 3 shows polynucleotides consisting of 5-100 consecutive DNA sequences comprising the 153923073 base of human chromosome 6, C or T (rs576496), and the 153923073 base; A polynucleotide consisting of 5-100 consecutive DNA sequences comprising the 111003744 base of the human chromosome 9, C or T (rs7021903), and the 111003744 base; A polynucleotide consisting of 5-100 consecutive DNA sequences comprising the 108135402 base of the human chromosome 6, which is T or C (rs6921267), and the 108135402 base; A polynucleotide consisting of 5-100 consecutive DNA sequences comprising 113245651 base of human chromosome 3 is G or A (rs7650263), and 113245651 base; A polynucleotide consisting of 5-100 consecutive DNA sequences comprising the 134456647 base of human human chromosome 2, G or A (rs16829881), and the 134456647 base; A polynucleotide consisting of 5-100 consecutive DNA sequences comprising the 134467821 base of human chromosome 2 (A rs2321546) with A or G, and the 134467821 base; A polynucleotide consisting of 5-100 consecutive DNA sequences comprising the 63359260 base of the human chromosome 18, G or C (rs9957826), and the 63359260 base; A polynucleotide consisting of 5-100 consecutive DNA sequences comprising the 4268219 base of human human chromosome 2, G or A (rs17018897), and the 4268219 base; A polynucleotide consisting of 5-100 consecutive DNA sequences comprising the 46170608 base of human human chromosome 2, A or T (rs1868273), the 46170608 base; A polynucleotide consisting of 5-100 consecutive DNA sequences comprising the 153943264 base of human chromosome 6, C or T (rs6920377), said 153943264 base; A polynucleotide consisting of 5-100 consecutive DNA sequences comprising the 46175944 base of the human chromosome 2, G or C (rs4953307), and the 46175944 base; A polynucleotide consisting of 5-100 consecutive DNA sequences comprising the 7547691616 base of human human chromosome 4 (Cs or T) (rs6446995), and the 75476916 base; A polynucleotide consisting of 5-100 consecutive DNA sequences comprising the 79763138 base of the human chromosome 9, C or T (rs11145633), the 79763138 base; A polynucleotide consisting of 5-100 consecutive DNA sequences comprising the 20125657th base of human chromosome 13, G or A (rs9506530), the 20125657th base; A polynucleotide consisting of 5-100 consecutive DNA sequences comprising the 111001210 base, wherein the 111001210 base of human chromosome 9 is C or T (rs7875754); A polynucleotide consisting of 5-100 consecutive DNA sequences comprising the 36732263 th base of human human chromosome 2, G or T (rs11883493), and the 36732263 th base; And at least one polynucleotide selected from the group consisting of complementary polynucleotides thereof. The marker may be a skin type diagnostic marker for judging whether the skin type is sensitive skin or sensitive skin.

The functions of the genes in which SNP markers are highly observed in a person with sensitive skin are as follows.

○ Chromosome 2

- gene: PRKCE (protein kinase C, protein kinase C, epsilon)

Function: Protein kinase C (PKC) is activated by calcium and diacylglycerol, a second messenger, as a serine and threonine-specific protein kinase family. Since the PKC family can phosphorylate many proteins, it is involved in various intracellular signal transduction. When PKC is activated, it strongly induces differentiation of keratinocytes. At least five PKC isoforms (α, δ, ε, η, ζ) exist in the epidermal layer of the skin. It is known that PKC affects the differentiation of keratinocytes and is involved in the response to foreign substances. As a potential candidate gene.

○ chromosome 6

- Upstream gene: OPRM1 (opioid receptor, opioid receptor, mu 1)

- Function: The OPRM1 gene encodes a mu-opioid receptor and is a receptor that binds opioid drugs such as morphine, heroin, and fentanyl. It is also a receptor for β-endorphin and enkephalin, which are endocrine opioid drugs, among neuroendocrine hormones secreted after stress. The μ-opioid receptor is known to be associated with tactile allodynia, which is likely to be a candidate gene that affects sensitive skin.

Therefore, it can be seen that SNP markers which are thought to be related when sensitive skin or skin function is considered, are sensitive to rs1868273, rs4953307, rs576496, and rs6920377 located on chromosome 6 on chromosome 2.

The present inventors confirmed that the above-mentioned SNP is a skin type diagnostic marker through the following proof. Specifically, sensitive skin was classified as Sting potential, Sting grade 0.4 or higher was classified as a sensitive skin test, and Sting grade 0.4 was classified as a control group. Metal allergic skin was classified as sensitive to metal (nickel) The skin condition was classified according to the conventional patch test method. GDNA was extracted from the saliva or blood from the classified individuals and genotype analysis experiments were performed with an Axiom (TM) ASI array plate (Fig. 1). As a result, SNPs having significance in sensitive skin types were classified (Tables 3 to 5). SNPs that can classify whether such skin types are sensitive are first identified by the present inventors.

In another aspect, the present invention provides a composition for diagnosing sensitivity of a skin type comprising a probe capable of detecting a marker for sensitivity diagnosis of the skin type or an agent capable of amplifying the skin type.

In the present invention, the term "probe capable of detecting a skin type sensitivity marker for detection of sensitivity" refers to a composition capable of diagnosing whether a skin type is sensitive by specifically hybridizing with a polymorphic site of the above- And the specific method of such gene analysis is not particularly limited and may be by any gene detection method known in the art to which this invention belongs.

In the present invention, the term "agent capable of amplifying a marker for sensitivity diagnosis of skin type" means a composition capable of diagnosing whether a skin type is sensitive by confirming a polymorphic site of such a gene through amplification, Preferably a primer capable of specifically amplifying the polynucleotide of the marker for sensitivity diagnosis of the skin type.

The primers used for the polymorphic marker amplification can be amplified by PCR using appropriate conditions in suitable buffers (e.g., four different nucleoside triphosphates and polymerase such as DNA, RNA polymerase or reverse transcriptase) and template-directed DNA Refers to a single stranded oligonucleotide that can serve as a starting point for synthesis. The appropriate length of the primer may vary depending on the intended use, but is usually 15 to 30 nucleotides. Short primer molecules generally require a lower temperature to form a stable hybrid with the template. The primer sequence need not be completely complementary to the template, but should be sufficiently complementary to hybridize with the template.

The term "primer" in the present invention means a base sequence having a short free 3 'hydroxyl group and can form base pairs with a complementary template, It means a short sequence functioning as a point. The primer can initiate DNA synthesis in the presence of reagents and four different nucleoside triphosphates for polymerization reactions (i.e., DNA polymerase or reverse transcriptase) at appropriate buffer solutions and temperatures. PCR amplification can be performed to predict skin type through the production of desired products. The PCR conditions, the lengths of the sense and antisense primers can be modified based on what is known in the art.

The probes or primers of the present invention can be chemically synthesized using the phosphoramidite solid support method, or other well-known methods. Such nucleic acid sequences may also be modified using many means known in the art. Non-limiting examples of such modifications include, but are not limited to, methylation, "capping ", replacement of natural nucleotides with one or more homologues, and modifications between nucleotides, such as uncharged linkers, such as methylphosphonate, Phosphoamidates, carbamates, etc.) or charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.).

In another aspect, the present invention provides a skin type diagnostic kit comprising the composition for diagnosing sensitivity of the skin type.

The kit may be an RT-PCR kit or a DNA chip kit.

The kit of the present invention can diagnose the skin type by confirming the SNP polymorphism marker which is a skin type diagnostic marker through amplification or by confirming the expression level of SNP polymorphism marker with the mRNA expression level. As a specific example, in the present invention, the kit for measuring the mRNA expression level of the skin type diagnostic marker may be a kit containing essential elements necessary for performing RT-PCR. In addition to the individual primer pairs specific for the genes of the skin type diagnostic marker, the RT-PCR kit also includes a test tube or other appropriate container, reaction buffer (pH and magnesium concentrations vary), deoxynucleotides (dNTPs) , Enzymes such as Taq polymerase and reverse transcriptase, DNase, RNAse inhibitors, DEPC-water, sterile water, and the like. It may also contain a primer pair specific for the gene used as a quantitative control. Also preferably, the kit of the present invention may be a skin type diagnostic kit containing essential elements necessary for carrying out a DNA chip. DNA chip kits are those in which nucleic acid species are attached in a gridded array on a generally flat solid support plate, typically a glass surface not larger than a slide for a microscope, and nucleic acids are uniformly arranged on the chip surface, Hybridization reaction occurs between the nucleic acid on the surface and the complementary nucleic acid contained in the solution treated on the surface of the chip to enable a mass parallel analysis.

In another aspect, the present invention provides a microarray for diagnosing sensitivity of a skin type comprising a polynucleotide of a marker for sensitivity diagnosis of the skin type.

The microarray may comprise DNA or RNA polynucleotides. The microarray comprises a conventional microarray except that the polynucleotide of the present invention is contained in the probe polynucleotide.

Methods for producing microarrays by immobilizing probe polynucleotides on a substrate are well known in the art. The probe polynucleotide means a polynucleotide capable of hybridizing, and means an oligonucleotide capable of binding to the complementary strand of the nucleic acid in a sequence-specific manner. The probe of the present invention is an allele-specific probe in which a polymorphic site exists in a nucleic acid fragment derived from two members of the same species and hybridizes to a DNA fragment derived from one member but does not hybridize to a fragment derived from another member . In this case, the hybridization conditions show a significant difference in the intensity of hybridization between alleles, and should be sufficiently stringent to hybridize to only one of the alleles. This can lead to good hybridization differences between different allelic forms. The probe of the present invention can detect an allele and can be used for diagnosis of skin type and the like. The diagnostic methods include detection methods based on hybridization of nucleic acids such as Southern blots, and may be provided in a form pre-bonded to a substrate of a DNA chip in a method using a DNA chip. The hybridization can usually be performed under stringent conditions, for example, a salt concentration of 1 M or less and a temperature of 25 ° C or higher. For example, conditions of 5x SSPE (750 mM NaCl, 50 mM Na Phosphate, 5 mM EDTA, pH 7.4) and 2530 [deg.] C may be suitable for allele-specific probe hybridization.

Immobilization on the substrate of the probe polynucleotide associated with the skin diagnosis of the present invention can also be easily made using this conventional technique. In addition, hybridization of nucleic acids on a microarray and detection of hybridization results are well known in the art. The detection can be accomplished, for example, by labeling the nucleic acid sample with a labeling substance capable of generating a detectable signal comprising a fluorescent material, such as Cy3 and Cy5, and then hybridizing on the microarray and generating The hybridization result can be detected.

In another aspect, the present invention provides a method for producing a DNA comprising: (a) obtaining DNA from a sample isolated from an individual; (b) amplifying the polymorphic site of the single nucleotide polymorphic marker from the DNA obtained in step (a) or hybridizing with the probe; And (c) identifying the base of the amplified or hybridized polymorphic site of step (b).

The term "individual" of the present invention means a subject for diagnosing whether the skin type is sensitive or not. DNA can be obtained from the sample, such as hair, urine, blood, various body fluids, isolated tissues, isolated cells or saliva, but is not limited thereto.

The method of obtaining the genomic DNA of step (a) may be any method known to those skilled in the art.

The amplification of the polymorphic site of the single nucleotide polymorphic marker from the DNA obtained in step (a) of step (b) or hybridization with the probe may be performed by any method known to those skilled in the art. For example, the target nucleic acid can be obtained by PCR amplification and purification thereof. Other ligase chain reaction (LCR) (Wu and Wallace, Genomics 4, 560 (1989), Landegren et al., Science 241, 1077 (1988)), transcription amplification (Kwoh et al., Proc. Natl. Acad. Sequence amplification based on nucleic acids (NASBA) can be used as well as self-sustaining sequence replication (Guatelli et al., Proc. Natl. Acad. Sci. USA 87, 1874 (1990)).

Determination of bases in the polymorphic site of step (c) of the above method can be performed by sequencing analysis, hybridization by microarray, allele specific PCR, dynamic allele-specifichybridization, DASH), PCR extension analysis, SSCP, PCR-RFLP analysis or TaqMan technique, SNPlex platform (Applied Biosystems), mass spectrometry (e.g., Sequenom's MassARRAY system), mini-sequencing method, Bio- But are not limited to, the BioRad system, the CEQ and SNPstream system (Beckman), the Molecular Inversion Probe array technology (e.g., Affymetrix GeneChip), and BeadArray Technologies (e.g. Illumina GoldenGate and Infinium assay). One or more alleles in a polymorphic marker, including microsatellite, SNP or other types of polymorphic markers, can be identified by such methods or by other methods available to those skilled in the art to which this invention pertains. The base of such a polymorphic site can be determined preferably through a SNP chip.

The term "SNP chip" in the present invention means one of DNA microarrays capable of confirming each base of several hundred thousand SNPs at a time.

The TaqMan method comprises the steps of: (1) designing and constructing a primer and a TaqMan probe to amplify a desired DNA fragment; (2) labeling probes of different alleles with FAM dyes and VIC dyes (Applied Biosystems); (3) performing PCR using the DNA as a template and using the primer and the probe; (4) after completion of the PCR reaction, analyzing and confirming the TaqMan assay plate with a nucleic acid analyzer; And (5) determining the genotype of the polynucleotides of step (1) from the analysis results.

In the above, the sequencing analysis can be performed using a conventional method for determining the nucleotide sequence, and can be performed using an automated gene analyzer. The allele-specific PCR means a PCR method in which a DNA fragment in which the SNP is located is amplified with a primer set including a primer designed with the base at the 3 'end at which the SNP is located. The principle of the above method is that, for example, when a specific base is substituted by A to G, an opposite primer capable of amplifying a primer containing the A as a 3 'terminal base and a DNA fragment of an appropriate size is designed, In the case where the base at the SNP position is A, the amplification reaction is normally performed and a band at a desired position is observed. When the base is substituted with G, the primer can be complementarily bound to the template DNA, And the amplification reaction is not performed properly due to the inability of complementary binding at the terminal. DASH can be performed by a conventional method, preferably by a method such as Prince et al.

On the other hand, in the PCR extension analysis, first, a DNA fragment containing a base in which a single base polymorphism is located is amplified by a pair of primers, and all nucleotides added to the reaction are deactivated by dephosphorylation, and SNP- specific extension primers, a dNTP mixture, a digoxin nucleotide, a reaction buffer, and a DNA polymerase to perform a primer extension reaction. At this time, the extension primer has a base immediately adjacent to the 5 'direction of the base in which the SNP is located at the 3' terminus, and the nucleic acid having the same base as the dodecoxynucleotide is excluded in the dNTP mixture, and the dodecoxynucleotide indicates the SNP Base type. For example, when dGTP, dCTP and TTP mixture and ddATP are added to the reaction in the presence of substitution from A to G, the primer is extended by the DNA polymerase in the base in which the substitution has occurred, The primer extension reaction is terminated by ddATP at the position where the base first appears. If the substitution has not occurred, the extension reaction is terminated at the position, so that it is possible to discriminate the type of the base representing the SNP by comparing the lengths of the extended primers.

As the detection method, when the extension primer or the dioxynucleotide is fluorescently labeled, the SNP is detected by detecting fluorescence using a gene analyzer (for example, Model 3700 of ABI Co., Ltd.) used for general nucleotide sequence determination And when the unlabeled extension primer and the didyxin nucleotide are used, the SNP can be detected by measuring the molecular weight using MALDI-TOF (matrix assisted laser desorption ionization-time of flight) technique.

Preferably, the method of providing information of the present invention comprises the steps of: (d) when the base of the amplified or hybridized polymorphic site is a minor allele, a control, which is the non-sensitive skin shown in Tables 3 to 5, If the frequency of the frequency of the test group is judged to be the skin of the group having a high frequency, and the base of the amplified or hybridized polymorphic region is a major allele, the sensitivity of the non-sensitive skin shown in Table 3 to Table 5 and the sensitivity And judging the skin of the lower group as the skin of the lower frequency group.

Preferably, if the single nucleotide polymorphism marker of step (b) is a single nucleotide polymorphism marker set forth in Table 5, it is determined whether the skin type is metal allergy sensitive to metals in the sensitive skin. Lt; / RTI > More preferably, (d) in the case where the base of the amplified or hybridized polymorphic site is a minor allele, a control, which is a skin without metal allergy, which is not sensitive to the metals shown in Table 5, and a metal allergy- The frequency of the skin test group is judged to be the skin of the high frequency group. If the base of the amplified or hybridized polymorphism region is a major allele, the control group, which is skin without metal allergy shown in Table 5, And judging the skin of the lower group as the frequency of the frequency of the allergic skin test group.

The single nucleotide polymorphic marker of the present invention is a marker capable of diagnosing skin characteristics for each individual, and can give information on the accurate skin type to an individual, thus providing a customized cosmetic according to the skin characteristics. In addition, by classifying the skin characteristics of cosmetics consumers scientifically, it is possible to develop tailor-made effective ingredients according to individuals and to develop customized cosmetics according to skin characteristics through various product segmentation.

1 is a schematic diagram of gene analysis using the Axiom (TM) ASI array plate of the present invention.
Figure 2 is a graph showing the log-value of the p-value with respect to the frequency of each SNP marker for sensitivity and the chromosomal location of the SNP.

Hereinafter, the present invention will be described in more detail with reference to Examples. These embodiments are only for illustrating the present invention, and the scope of the present invention is not construed as being limited by these embodiments.

Example 1: Characterization of Skin and Gene Collection

In order to establish skin classification standards for genotypes and to develop a personalized active ingredient, the inventors of the present invention conducted a study to examine the skin characteristics of healthy female subjects aged from 20 to 50 years old. In order to classify their skin characteristics, 81 subjects who met the subject selection criterion of the present invention and 20 persons who completed whitening skin classification in the dermatology department of Gyeongsang National University were selected from the basic data of the subjects held by Derma Pro Co., (Table 1). The sample means saliva or blood. For example, the saliva was collected twice, and the first saliva was collected after subjects were fasted one hour before collection, and the second saliva was obtained immediately after the morning wake.

Each classification was performed according to the following criteria.

○ Sensitivity classification: Sensitivity was classified according to sting potential in Sting potential test. Sting grade 0.4 or higher was used for sensitive skin test and Sting grade 0.4 was used for control.

Classification The control (control) The test case Skin sensitivity Sting grade less than 0.4 Sting grade 0.4 or higher

If you are pregnant or breastfeeding, or if you plan to become pregnant within 6 months, (2) you have used steroid-containing skins for at least one month to treat skin conditions, (3) you have not taken more than six months ⑤ If you have sensitive or irritable skin, ⑤ If you have skin abnormalities such as dots, acne, erythema and capillary dilatation on the test site. ⑥ You can not apply the same or similar cosmetics or medicines ⑦ If you have a chronic wasting disease (asthma, diabetes, hypertension, etc.), ⑨ If you have atopic dermatitis, ⑩ Other cases In cases where it was judged by the examiner that the examination was difficult, the subjects were excluded.

Example 2: Analysis of genotypes according to skin characteristics

Genotyping of the skin type samples was performed using the Affymetrix Axiom (TM) ASI array plate.

In order to determine the sensitivity of the skin type according to the criteria of Example 1, the skin type consisted of 20 persons in each of 10 test groups and 10 control groups in each group, and gDNA was extracted from saliva in the forty female subjects.

The saliva or blood of women in each group was extracted with QIAmp mini gDNA prep kit (QIAGEN, Korea) and OD260 / 280> 1.7, more than 10ng / ㎕, 1xTAE 1% agarose gel, After confirming the band, the genotype analysis experiment was carried out. Genomic assays using the Axiom ASI plate were performed in accordance with the manual. The reagents contained in the Axiom ASI plate kit were used for amplification of gDNA, DNA fragmentation, quality control, hybridization, staining, and scanning. The image of the chip was scanned using the GeneTitan MC (Affymetrix) system and the CeneChip Command Console Software (AGCC), and the scanned image dat file was automatically converted into a cel file by the AGCC. The cel file for each chip was subjected to data quality control and genotype call using genotyping console 4 program. A general schematic diagram of a method for gene analysis using the Affymetrix Axiom (TM) ASI array plate is shown in FIG.

A total of 20 genotyping chip experiments were conducted, and one sample of the control group failed to pass QC, resulting in no genotyping results. QC standards are passed if the DISHQC value of the Axiom Chip is greater than 0,82 and the genotype call rate is more than 97%.

Example 3 Detection of Sensitive Skin Type Related Genotype Using Genotype Analysis by Skin Type

In order to detect genotypes associated with skin type, association analysis using SNP markers of test group / control group was performed in each group. For this, we used the PLINK 1.07 program and set MAF (Minor Allele Frequency)> 0.1 and Hardy-Weinberg Equilibrium (HWE)> 0.001 as QC parameters for each marker.

The test group / control group were compared, and the number of data used in the comparison was as follows (Table 2). The final major SNP markers predicted to be associated with the skin type selected only the Affymetrix SNP annotation associated with the skin type, with a significance level of the chi-square test for each allele of p <0.0001 or less, or p <0.01.

The test case The control (control) Number of SNPs sensitive 10 9 24

In addition, a significant level of chi-square test for sensitivity and metal allergy was selected to be p < 0.01.

3-1: Investigation of genetic polymorphism of sensitive skin and selection of significant SNP

The log-value of the p-value with respect to the frequency of each marker in the association analysis results related to sensitivity and the chromosomal location of the SNP are shown in FIG. As a result, it was confirmed that SNP markers having high significance exist sporadically throughout the chromosome. A list of key SNP markers significantly associated with such sensitivity is shown in Table 3 below.

In Table 3, rs1868273, rs4953307 minor allele located on chromosome 2, minor allele of rs7650263 located on chromosome 3, rs576496 located upstream and downstream of chromosome 6, The minor allele of rs6921267, rs6920377, and rs7021903, located on chromosome 9, were present at a high frequency in the test group (sensitive skin), while the control group (non-sensitive skin) was detected at a relatively low frequency (Table 3). Thus, minor alleles of these SNP markers are highly likely to be associated with sensitive skin. Among the highly-observed SNP markers in sensitive skin, rs1868273, minor allele of rs4953307 located on chromosome 2, minor allele of rs7650263 located on chromosome 3, rs576496, rs6921267, rs6920377 located upstream and downstream of chromosome 6 The minor allele, rs7021903, located on chromosome 9, was present at a high frequency in the test group (sensitive skin), while in the control (non-sensitive skin) it was detected at a relatively low frequency (Table 3). Thus, minor alleles of these SNP markers are highly likely to be associated with sensitive skin.

The SNP marker list with p <0.01 significantly associated with sensitivity is shown in Table 4 below.

3-2: Survey of genetic polymorphism of metal allergy skin and selection of significant SNP

A SNP marker list of p <0.001, which is significantly related to the results of association analysis with metal allergies in sensitive skin, is shown in Table 5 below. Skin metal allergy classification was confirmed by routine patch testing.

Claims (5)

A composition for diagnosing sensitivity of a skin type comprising a probe capable of detecting a single nucleotide polymorphism (SNP) marker for diagnosing sensitivity of a skin type or an amplifiable agent,
The single nucleotide polymorphism marker for detecting the sensitivity of the skin type is a polynucleotide consisting of 5-100 consecutive DNA sequences comprising the 153943264 base of human chromosome 6 (rs6920377) containing C or T (rs6920377) Or a complementary polynucleotide thereof. &Lt; / RTI &gt;
A kit for diagnosing the sensitivity of a skin type comprising the composition of claim 1.
A microarray for diagnosing sensitivity of a skin type, comprising a single nucleotide polymorphism (SNP) marker for diagnosing sensitivity of a skin type,
The single nucleotide polymorphism marker for detecting the sensitivity of the skin type is a polynucleotide consisting of 5-100 consecutive DNA sequences comprising the 153943264 base of human chromosome 6 (rs6920377) containing C or T (rs6920377) Or a complementary polynucleotide thereof. &Lt; RTI ID = 0.0 &gt; 11. &lt; / RTI &gt;
(a) obtaining DNA from a sample isolated from an individual;
(b) amplifying or hybridizing a polymorphic site of a single nucleotide polymorphism (SNP) marker for skin type sensitivity diagnosis from the DNA obtained in step (a)
The single nucleotide polymorphism marker for detecting the sensitivity of the skin type is a polynucleotide consisting of 5-100 consecutive DNA sequences comprising the 153943264 base of human chromosome 6 (rs6920377) containing C or T (rs6920377) Or a complementary polynucleotide thereof; And
(c) identifying a base of the amplified or hybridized polymorphic site of step (b).
5. The method according to claim 4, wherein (d) the base of the amplified or hybridized polymorphic site is T, it is judged to have a sensitive skin, and when the base of the amplified or hybridized polymorphic site is C, Wherein the method further comprises the step of determining whether the skin type is sensitive.

Images